Response Oncology Performance
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Response Oncology are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Response Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong forward indicators, Response Oncology is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
Response |
Response Oncology Relative Risk vs. Return Landscape
If you would invest (100.00) in Response Oncology on November 16, 2025 and sell it today you would earn a total of 100.00 from holding Response Oncology or generate -100.0% return on investment over 90 days. Response Oncology is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Response, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Response Oncology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Response Oncology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Response Oncology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Response Oncology is not yet fully synchronised with the market data | |
| Response Oncology has some characteristics of a very speculative penny stock | |
| Response Oncology has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 118.08 M. Net Loss for the year was (51.39 M) with profit before overhead, payroll, taxes, and interest of 28.17 M. |
Response Oncology Fundamentals Growth
Response Stock prices reflect investors' perceptions of the future prospects and financial health of Response Oncology, and Response Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Response Stock performance.
| Return On Equity | -7.24 | |||
| Return On Asset | -0.0153 | |||
| Profit Margin | (0.47) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 16.62 M | |||
| Shares Outstanding | 12.18 M | |||
| Revenue | 118.08 M | |||
| EBITDA | 1.32 M | |||
| Cash And Equivalents | 9.01 M | |||
| Cash Per Share | 0.74 X | |||
| Total Debt | 26.45 M | |||
| Book Value Per Share | (1.54) X | |||
| Cash Flow From Operations | 9.1 M | |||
| Earnings Per Share | (4.16) X | |||
| Total Asset | 28.9 M | |||
| Retained Earnings | (120.16 M) | |||
| Current Asset | 37.25 M | |||
| Current Liabilities | 2.54 M | |||
Things to note about Response Oncology performance evaluation
Checking the ongoing alerts about Response Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Response Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Response Oncology is not yet fully synchronised with the market data | |
| Response Oncology has some characteristics of a very speculative penny stock | |
| Response Oncology has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 118.08 M. Net Loss for the year was (51.39 M) with profit before overhead, payroll, taxes, and interest of 28.17 M. |
- Analyzing Response Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Response Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Response Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Response Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Response Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Response Oncology's stock. These opinions can provide insight into Response Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Response Stock
If you are still planning to invest in Response Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Response Oncology's history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |